MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) Initiates Collaboration With Bakoulev Center for Developing Next Generation Cardiac Stem Cell Therapeutics

SAN DIEGO, CA--(Marketwire - May 11, 2011) - Medistem Inc. (PINKSHEETS: MEDS) announced today a collaboration with the Bakoulev Center of Cardiovascular Surgery of Russian Academy of Sciences. The collaboration will focus on clinical development of Medistem's Universal Donor Endometrial Regenerative Cell (ERC) stem cell for treatment of patients with heart failure.

"The support of the Bakoulev Center in performing clinical evaluation of our ERC stem cell in accordance with internationally recognized Good Clinical Practices is a strong signal supporting our research program. Researchers at the Bakoulev Center have pioneered numerous technological advancements in cardiology internationally, as well as being the first to use bone marrow stem cells in Russia. We are honored to be collaborating with an Institute of this stature," said Vladimir Zaharchook, Vice Chairman and Vice President of Medistem Inc.

The Bakoulev Center for Cardiovascular Surgery of Russian Academy of Medical Sciences is considered Russia's Premier center for cardiovascular surgery and cardiology. Every year the Bakoulev Center performs approximately 30,000 diagnostic and treatment procedures, which includes 7,000 open heart surgeries and more than 12,000 angioplasties.

"Medistem's ERC stem cell is unique not only in its source but also in its ability to produce greater amounts of cardiac-relevant therapeutic factors as compared to other stem cells," said Prof. Bockeria. "We look forward to working with Medistem on developing what could be the next generation of stem cell therapies."

The ERC was discovered in 2007 by Medistem scientists (http://www.translational-medicine.com/content/pdf/1479-5876-5-57.pdf), which won the Publication of the Year award from BioMed Central, publisher of over 200 journals. Recently Medistem reported in the peer-reviewed literature that administration of ERC into a heart failure patient resulted in remission (http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf). The current collaboration will assess whether these findings can be duplicated in a larger number of patients.

About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. ERC can be purchased for scientific use through Medistem's collaborator, General Biotechnology, http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.

Cautionary Statement
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.